QalibreMD and qMRI News

Press Releases

Read QMD Press Releases

In the News

Read QalibreMD in the News

qMRI News

Coming Soon

Press Releases

QalibreMD Receives $1.7M Grant from NIH to Advance Monitoring of Breast Cancer Treatment

For Immediate Release                                           

Contact: Kevin Miller,, (303) 447-2558

BOULDER, Colorado, November 13, 2018 – QalibreMD, a startup focused on transforming MRI technology, received a $1.72 million grant from the National Cancer Institute, part of the NIH, to mature and test its quantitative MRI (qMRI) technology, the qCal-MR platform, at 12 ISPY 2 clinical sites. The focus of ISPY 2 clinical trial is the rapid evaluation of neoadjuvant (before surgery) drug treatments of breast cancer.

QalibreMD, University of California at San Francisco (UCSF), and the National Institute of Standards and Technology (NIST) are partnered to develop the qCal-MR based on prior joint research and development.

qCal-MR aims to remedy one of the most glaring problems in MRI practice: standardization and quantification of the qMRI image output so that, for example, breast cancer diagnostics, monitoring, and treatment efficacy assessment could be made independent of particular MRI device performance and protocols used. qCal-MR will save breast cancer patients from unnecessary, costly, and invasive procedures.

Traditional MRI scans can result in a 40% variability between readings on different equipment. The results can be costly and misleading, as cancer can go undiagnosed or misdiagnosed. qCal-MR standardizes all MRI equipment currently used in research and clinical settings using a combination of hardware reference standards called phantoms and machine learning software systems.

Dr. Todor Karaulanov, Principal Investigator on the NIH grant, says, “QalibreMD staff, in partnership with UCSF and NIST, is very excited to take on the mandate provided by the National Cancer Institute grant to enable true quantitative MRI measurements. The successful implementation of qCal-MR in the paradigm-shifting I-SPY 2 clinical trial will help qualify breast cancer drugs by removing variability in MRI equipment and protocols.”      

QalibreMD is a subsidiary company of High Precision Devices, both based in Boulder, Colorado. Founded in 2017, QalibreMD is focused on transforming medical imaging through quantification and standardization of traditional MRI equipment. More information about QalibreMD can be found at

QalibreMD in the News

QalibreMD on KGNU Radio: MRI Improvement by Standardization

Click here to listen to the CEO of QalibreMD, William Hollander, and Director of Business Development, Kevin Miller, on Boulder’s KGNU Radio.

QalibreMD, a subsidiary company of High Precision Devices 
QalibreMD, a subsidiary company of High Precision Devices